亮丙瑞林、曲普瑞林：新适应症。局部晚期前列腺癌：最低限度评估的仿制药。
Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
出版信息
Prescrire Int. 2007 Dec;16(92):243.
PMID:18092407
Abstract
Unlike goserelin, leuprorelin and triptorelin have not been assessed for their impact on survival in patients with locally advanced prostate cancer. The main adverse effects of these two drugs are similar, but convenience of use differs.
摘要
与戈舍瑞林不同，亮丙瑞林和曲普瑞林对局部晚期前列腺癌患者生存影响尚未得到评估。这两种药物的主要不良反应相似，但使用便利性有所不同。
Zotero 插件